USANA HEALTH SCIENCES INC (USNA) stock intrinsic value fair value estimate & owner earnings analysis

USANA Health Sciences sells nutritional supplements, foods and personal care products, mostly through independent distributors ("Brand Partners") around the world. Its single largest market by far is Mainland China, which alone accounted for about 41% of total net sales in fiscal 2025 (down from about 48% the year before), with Hong Kong and Taiwan adding a bit more on top of that — together, Greater China was roughly 46% of the company's sales in 2025. That concentration is central to how the business should be valued: this is a U.S. company, but its fortunes ride heavily on Chinese consumer demand and on China's regulatory treatment of direct-selling businesses, which has tightened at times over the past several years. In December 2024 USANA bought a 78.85% stake in Hiya, a subscription children's-vitamin brand sold online, for about $206 million in cash, adding a second, U.S.-centered growth channel alongside the older distributor business. It also owns a smaller, still-unprofitable newer brand, Rise. The core distributor business has been shrinking. Active customers fell nearly 15% during 2025 to 387,000, with declines across every region, and core segment operating earnings fell from about $96 million in 2023 to about $71 million in 2024 to roughly $41 million in 2025 (about $53 million before a one-time cost-realignment charge and a small non-cash write-down of a wholesale unit). Hiya's first full year under USANA ownership, 2025, produced about $132 million of revenue, but subsequent results have shown Hiya's subscriber growth cooling as digital-advertising costs have risen — since paid advertising is how a subscription brand like this acquires nearly all of its customers. We were not able to independently confirm the precise subscriber figures behind that from the sources available to us this time, though the company's own reported revenue for the first half of 2026 is down modestly (about 2% year over year) in a pattern consistent with that softness. Because USANA paid for Hiya's existing customer relationships and brand, it now writes down a portion of that purchase price every year — about $19 million in 2025 alone — as a non-cash accounting charge. That charge doesn't reduce actual cash earnings, so we add it back when measuring what a shareholder actually earns. But that add-back is only right if the customers being written off are being replaced by new ones. Through 2025 that was a reasonable assumption; with subscriber growth now under pressure, it's less clear, so rather than double-counting that erosion in today's earnings figure, we've built it into how far we expect this piece of the business to grow going forward. Two other accounting points worth knowing. First, USANA owns only 78.85% of Hiya; the remaining owners can require USANA to buy out half their stake starting in April 2028 and the rest starting in April 2030, at a price tied to a multiple of Hiya's profits — so roughly a fifth of Hiya's cash generation doesn't ultimately belong to USANA's shareholders. Second, USANA earns most of its profit in Asia but incurs a large share of its costs in the United States; as U.S. income has shrunk, the tax bill hasn't shrunk with it, so the effective tax rate jumped to about 72% in 2025 from about 45% in 2024, and management expects it to stay elevated. We haven't assumed it normalizes. We measure the cash the business actually generates for its owners each year — operating cash flow, minus what it takes to keep the business running (not what it takes to grow it), minus stock compensation, and stripped of swings in inventory and payables timing. On that basis, the company generated about $3.60 a share in 2023, $2.58 in 2024, and $2.09 in 2025 — a real decline, not a one-off. We use $2.58, the middle of those three years, as our starting point, adjusted down slightly (to about $2.43) to reflect the roughly fifth of Hiya's earnings that belongs to its other owners. We deliberately exclude 2020-2021, when pandemic-era demand temporarily inflated supplement sales, and years before 2022, when the core China business was a meaningfully larger part of the company than it is today. Our bear case assumes China customer losses continue at the mid-teens pace seen in 2025, core sales fall from around $750 million today toward under $500 million over the next decade, and the fixed cost of running USANA's manufacturing and distribution base can't be trimmed fast enough, squeezing margins further. Hiya's subscriber losses continue at roughly 10% a year until its contribution fades to nearly nothing by the early 2030s, and Rise is wound down. A credit-facility covenant requires trailing four-quarter earnings (before interest, tax, depreciation and amortization) of at least $80 million; a further slide would put use of that facility at risk. On this path, owner earnings settle near $1.00 a share, and we estimate the shares are worth roughly $19. Our base case assumes the core business finds a floor near $700 million of sales at roughly a 7% operating margin, aided by the cost realignment started in late 2025 — and encouragingly, Greater China revenue was roughly flat in the first half of 2026 after two years of decline, a real, dated data point rather than a hope. Hiya's 2026 stumble marks its low point, with a return to modest growth from 2028; Rise reaches breakeven around 2029; and USANA continues retiring roughly 1.5% of its shares a year, a pattern that has taken the share count from about 25 million in 2016 to about 18.6 million today. On this path, owner earnings recover to about $2.10 next year and drift up to roughly $2.60 a share by the mid-2030s, and we estimate the shares are worth roughly $44. Our bull case assumes the digital-advertising cost spike pressuring Hiya proves temporary rather than permanent, Hiya returns to double-digit growth from 2028, Rise grows past $100 million at a positive margin, and Greater China's customer base stabilizes behind new product launches. On this path, owner earnings roughly double over the decade to about $4.00 a share, and we estimate the shares are worth roughly $66. The wide range reflects two separate open questions: whether the China business has further to fall, and whether the Hiya acquisition will prove to be a good use of the company's cash. The balance sheet is a real cushion either way — about $168 million of cash as of the most recent quarter (nearly $9 a share), with the revolving credit line paid off — which is a large part of why even our bear case is a smaller business rather than a distressed one. The margin-of-safety price is about $26 — close to a 40% discount to our base-case estimate, reflecting genuine uncertainty rather than a mechanical formula. That price also depends on Hiya's subscriber count ceasing to decline, and Greater China's active customer count following its revenue toward stabilization; those two things are what separate our bear case from our base case, and neither has fully happened yet, though the flattening of Greater China revenue in the first half of 2026 is an early, favorable sign.